


**REMARKS**

No new matter has been added by these amendments. Applicants respectfully request entry of the present amendment.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: 26, November 2001

  
Shirley A. Recipon  
Reg. No. 47,016  
Direct Dial Telephone: (650) 621-8555

3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 845-4166

**VERSION WITH MARKINGS TO SHOW CHANGES MADE****IN THE SPECIFICATION:**

**Paragraph beginning at line 23 of page 26 has been amended as follows:**

The columns of Table 3 show the tissue-specificity and diseases, disorders, or conditions associated with nucleotide sequences encoding EXCS. The first column of Table 3 lists the nucleotide SEQ ID NOs. Column 2 lists fragments of the nucleotide sequences of column 1. These fragments are useful, for example, in hybridization or amplification technologies to identify SEQ ID NO:27-52 and to distinguish between SEQ ID NO:27-52 and related polynucleotide sequences. The polypeptides encoded by these fragments are useful, for example, as immunogenic peptides. Column 3 lists tissue categories which express EXCS as a fraction of total tissues expressing EXCS. Column 4 lists diseases, disorders, or conditions associated with those tissues expressing EXCS as a fraction of total tissues expressing EXCS. Of particular note is the expression of SEQ ID NO:30. This sequence is detected in six cDNA libraries, all of which were constructed independently using RNA isolated from prostate tissue. Therefore, SEQ ID NO:30 is useful, for example, as a prostate-specific marker for tissue-typing and for diagnosis of diseases of the prostate. [SEQ ID NO:43] SEQ ID NO:42 is specifically expressed in islet cells and in islet cell tumor only. Of particular note is the expression of SEQ ID NO:45 exclusively in hematopoietic/immune tissues. Column 5 lists the vectors used to subclone each cDNA library.